With use of 27.B1 and 27.F7 human monoclonal antibody specific to GIPC-1 protein, Yavelsky et al. [83] demonstrated a positive immunnohistochemical staining for GIPC-1, respectively, in 24/25 (96%) and 11/23 (48%) breast ductal carcinomas, 9/10 (90%) and 8/15 (53%) breast lobular carcinomas, 0/4 and 0/4 breast ductal carcinomas in situ, 0/4 and 0/4 breast lobular carcinomas in situ, 0/4 and 0/4 breast fibroadenomas, and 0/4 and 0/4 breast hyperplasias. This evidence concerns the gene GIPC1 and breast ductal adenocarcinoma.